Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | IL2 | P60568 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 3/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | CCKAR | P32238 | 2/20 | 0.35 |
| ▸ | PLG | P00747 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.34 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.34 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342513 | 1.00 | OPRK1 (0.39) | OPRK1TTRIL2CCKBRF2R | |
| SCHEMBL12342493 | 0.96 | OPRK1 (0.40) | OPRK1TTRIL2CCKBRF2R | |
| SCHEMBL12377406 | 0.95 | CCKBR (0.39) | OPRK1TTRIL2CCKBRF2R | |
| SCHEMBL14329043 | 0.94 | CCKBR (0.39) | OPRK1TTRIL2CCKBRF2R | |
| SCHEMBL25795377 | 0.91 | CCKBR (0.40) | TTRIL2CCKBRFOLH1CCKAR | |
| SCHEMBL12342504 | 0.89 | TTR (0.44) | OPRK1TTRIL2CCKBRF2R | |
| SCHEMBL22969740 | 0.89 | TTR (0.38) | OPRK1TTRIL2F2RFOLH1 | |
| SCHEMBL23180460 | 0.84 | TTR (0.37) | OPRK1TTRIL2F2RFOLH1 | |
| SCHEMBL24176337 | 0.83 | TTR (0.37) | OPRK1TTRIL2F2RFOLH1 | |
| SCHEMBL29351004 | 0.83 | TTR (0.46) | TTRIL2F2RFOLH1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166363-A1 | Improved targetting | IMMUNOMEDICS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166363-A1 | Improved targetting | CD47, CYTH3, FCGR2A | OPRK1 4728/4885TTR 4273/4885IL2 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.